Likewise, Baris et al. [42] compared epigenetic alterations in the target gene Enhancer of Zeste Homolog-2 (EZH-2) between plasma-derived exosomes and matched primary tumor tissues of 21 patients with aggressive diffuse large B cell lymphoma (DLBCL). This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.